News

Deal Announcements

Fovea Pharma Secures $44 Million Series B

Friday, December 14, 2007 5:30:00 AM PDT | VentureDeal Staff
NEW YORK, NY -- Ocular disease pharmaceutical company Fovea Pharmaceuticals, Inc. announced that it has raised $44 million in series B venture capital financing.

Fovea is developing drug treatments for ocular diseases such as retinal degeneration, glaucoma, dry eye, allergy and inflammation.

The company's previous investors participated in the round along with new investor Forbion Capital Partners.  Previous investors were Sofinnova Ventures, Abingworth Management, GIMV, The Wellcome Trust and Credit Agricole Private Equity.

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin


PCI - Level1